173 related articles for article (PubMed ID: 38637848)
1. Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy.
Guo Y; Wu J; Chen L; Liu L; Bi T; Pan Y; Meng QF; Wang C; Rao L; Li Q
J Nanobiotechnology; 2024 Apr; 22(1):192. PubMed ID: 38637848
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Cellular Nanovesicles Block PD-L1 Signal and Repolarize M2 Macrophages for Cancer Immunotherapy.
Zhao C; Pan Y; Liu L; Zhang J; Wu X; Liu Y; Zhao XZ; Rao L
Small; 2024 Mar; ():e2311702. PubMed ID: 38456371
[TBL] [Abstract][Full Text] [Related]
3. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.
Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC
Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482
[TBL] [Abstract][Full Text] [Related]
4. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
McCarty MF; Hejazi J; Rastmanesh R
Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
[TBL] [Abstract][Full Text] [Related]
5. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.
Rao L; Wu L; Liu Z; Tian R; Yu G; Zhou Z; Yang K; Xiong HG; Zhang A; Yu GT; Sun W; Xu H; Guo J; Li A; Chen H; Sun ZJ; Fu YX; Chen X
Nat Commun; 2020 Sep; 11(1):4909. PubMed ID: 32999291
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation and immunotherapy for the treatment of prostate cancer.
Gamat M; McNeel DG
Endocr Relat Cancer; 2017 Dec; 24(12):T297-T310. PubMed ID: 28814451
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.
Wang S; Huang M; Chen M; Sun Z; Jiao Y; Ye G; Pan J; Ye W; Zhao J; Zhang D
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295817
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
9. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer.
El-Kenawi A; Dominguez-Viqueira W; Liu M; Awasthi S; Abraham-Miranda J; Keske A; Steiner KK; Noel L; Serna AN; Dhillon J; Gillies RJ; Yu X; Koomen JM; Yamoah K; Gatenby RA; Ruffell B
Cancer Res; 2021 Nov; 81(21):5477-5490. PubMed ID: 34301759
[TBL] [Abstract][Full Text] [Related]
10. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
11. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.
Siddiqui IA; Asim M; Hafeez BB; Adhami VM; Tarapore RS; Mukhtar H
FASEB J; 2011 Apr; 25(4):1198-207. PubMed ID: 21177307
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer.
Qin C; Wang J; Du Y; Xu T
Front Endocrinol (Lausanne); 2022; 13():1055826. PubMed ID: 36506053
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer.
Han S; Shi T; Liao Y; Chen D; Yang F; Wang M; Ma J; Li H; Xu Y; Zhu T; Chen W; Wang G; Han Y; Xu C; Wang W; Cai S; Zhang X; Xing N
J Transl Med; 2023 Mar; 21(1):194. PubMed ID: 36918939
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor dampens tissue factor expression via nuclear factor-κB and early growth response protein 1.
Hoesel B; Mussbacher M; Dikorman B; Salzmann M; Assinger A; Hell L; Thaler J; Basílio J; Moser B; Resch U; Paar H; Mackman N; Schmid JA
J Thromb Haemost; 2018 Apr; 16(4):749-758. PubMed ID: 29427323
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Hawley JE; Obradovic AZ; Dallos MC; Lim EA; Runcie K; Ager CR; McKiernan J; Anderson CB; Decastro GJ; Weintraub J; Virk R; Lowy I; Hu J; Chaimowitz MG; Guo XV; Zhang Y; Haffner MC; Worley J; Stein MN; Califano A; Drake CG
Cancer Cell; 2023 Nov; 41(11):1972-1988.e5. PubMed ID: 37922910
[TBL] [Abstract][Full Text] [Related]
16. Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance.
Peng G; Wang C; Wang H; Qu M; Dong K; Yu Y; Jiang Y; Gan S; Gao X
Oncoimmunology; 2023; 12(1):2173422. PubMed ID: 36776524
[TBL] [Abstract][Full Text] [Related]
17. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
Brown NE; Jones A; Hunt BG; Waltz SE
Prostate; 2022 Nov; 82(15):1422-1437. PubMed ID: 35860905
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer.
Johnson RP; Ratnacaram CK; Kumar L; Jose J
Drug Resist Updat; 2022 Sep; 64():100865. PubMed ID: 36099796
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells.
Gupta S; Ahmad N; Nieminen AL; Mukhtar H
Toxicol Appl Pharmacol; 2000 Apr; 164(1):82-90. PubMed ID: 10739747
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
